Mohammed Qatanani
Net worth: 4 M $ as of 2026-10-30
Net worth: 4 M $ as of 2026-10-30
Dr. Mohammed Qatanani is a Chief Scientific Officer at Scholar Rock Holding Corp.
Dr. Qatanani was previously employed as a Vice President-Program & Alliance Management by Dyne Therapeutics, Inc. and a Director-Discovery Research by Alexion Pharmaceuticals, Inc. He received his undergraduate degree from American University of Beirut, a graduate degree from American University of Beirut and an MBA from Baylor College of Medicine.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-02-22 | 98,445 ( 0.08% ) | 4 M $ | 2026-10-30 |
| Companies | Position | Start |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Chief Tech/Sci/R&D Officer | 2022-08-31 |
| Companies | Position | End |
|---|---|---|
| DYNE THERAPEUTICS, INC. | Corporate Officer/Principal | 2021-08-31 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2017-12-31 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 5 |
|---|---|
Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
American University of Beirut
American University of Beirut Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baylor College of Medicine
Baylor College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Scholar Rock Holding Corp.
Scholar Rock Holding Corp. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focused on the discovery, development and delivery medicines for neuromuscular, cardiometabolic disorders, cancer, fibrosis and iron-restricted anemia | Health Technology |
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics to treat muscle diseases | Health Technology |
Select your edition
All financial news and data tailored to specific country editions